Lenvatinib treatment strategy for thyroid carcinoma with malignant pleurisy: a case report
The presence of malignant pleurisy results in a risk of developing lenvatinib-associated pneumothorax. Therefore, pleurodesis should be considered before lenvatinib therapy for thyroid carcinomas with malignant pleurisy.
Authors
- Shinichi Sakamoto (ORCID: https://orcid.org/0000-0002-7508-7521)
- Seiya Inoue (ORCID: https://orcid.org/0000-0003-0945-0000)
- Naoki Miyamoto (ORCID: https://orcid.org/0000-0002-6337-6211)
- Hiromitsu Takizawa (ORCID: https://orcid.org/0000-0001-7822-6294)
- Hiroaki Toba
- Masakazu Goto (ORCID: https://orcid.org/0000-0002-4209-5218)
- Keisuke Fujimoto (ORCID: https://orcid.org/0000-0002-2045-0952)
- Satoshi Fujiwara
- Taihei Takeuchi
- Mariko Misaki
Institutions
- Tokushima University (JP)
Publication Details
- Journal
- Gland Surgery
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/gs-24-269
- Citations
- 1
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.36